Deals In Depth: June/July 2013

In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.

Link:
Deals In Depth: June/July 2013

Tags: , , , , , , , , , ,

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Contact Us

Click or drag a file to this area to upload.